August 19, 2024

Funding from Business Finland

OncoBone has received funding from Business Finland for piloting its Bone Metastasis Technology Platform (BMTP), a novel platform for evaluating preclinical efficacy of novel therapies on bone metastasizing cancers. Bone metastases are life-threatening and a high unmet medical need with no curative treatments available.

Jussi Halleen, CEO of OncoBone says: “We are thankful to Business Finland for the support. BMTP is a reliable translational tool for decreasing the current high rate of costly failures in oncology clinical trials due to poor efficacy and improving the entrance of truly effective oncology drugs to the market.”